MSD's Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...

The approval was based on data from the pivotal Phase IIb/III CLEVER trial which assessed a single dose of the antibody.

The interactive version of the crossword that appears in Thursday’s Farming supplement. No cheating.

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

The green light in the US is the first worldwide for Enflonsia ( clesrovimab) and makes the long-acting antibody the first ...

Scientists at the Broad Institute of MIT and Harvard have identified 4,208 previously unannotated open reading frames (ORFs) across 679 human-associated viral genomes using a high-throughput method ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

For the first time since the start of the COVID-19 pandemic, the number of Nova Scotians dying from influenza exceeds that of ...